MedTrace Logo

Combination Chemotherapy Following Surgery in Treating Women With Early Stage Breast Cancer

NCT00003012 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2013-11-06

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective following surgery for breast cancer.

PURPOSE: Randomized phase III trial to study the effectiveness of combination chemotherapy consisting of cyclophosphamide, methotrexate, and fluorouracil with or without epirubicin in treating women who have early stage breast cancer.

Conditions

Interventions

DRUG

CMF regimen

DRUG

cyclophosphamide

DRUG

epirubicin hydrochloride

DRUG

fluorouracil

DRUG

methotrexate

Sponsors & Collaborators

  • Scottish Cancer Therapy Network

    lead OTHER

Principal Investigators

  • Chris Twelves, MD, BMedSci, FRCP · University of Glasgow

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003012 on ClinicalTrials.gov